DT2216 —a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through upregulation of anti-apoptotic Bcl-2 proteins. Subsets of TC...

Source: Journal of Hematology and Oncology - July 16, 2020 Category: Hematology Authors: Yonghan He, Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan, Dinesh Thummuri, Yuma T. Ortiz, Xin Zhang, Dongwen Lv, Janet S. Wiegand, Wen Li, Adam C. Palmer, Guangrong Zheng, David M. Weinstock and Daohong Zhou Tags: Research Source Type: research